{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T03:07:15Z","timestamp":1777777635986,"version":"3.51.4"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T00:00:00Z","timestamp":1602806400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2020.593289","type":"journal-article","created":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T04:36:26Z","timestamp":1602822986000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":19,"title":["Chronic Mucocutaneous Candidiasis in Early Life: Insights Into Immune Mechanisms and Novel Targeted Therapies"],"prefix":"10.3389","volume":"11","author":[{"given":"Oded","family":"Shamriz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuval","family":"Tal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aviv","family":"Talmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Nahum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ1194","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of america","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/odi.12881","article-title":"Chronic mucocutaneous candidiasis due to gain-of-function mutation in STAT1","volume":"25","author":"Carey","year":"2019","journal-title":"Oral Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2177\/jsci.40.109","article-title":"CMCD: chronic mucocutaneous candidiasis disease","volume":"40","author":"Okada","year":"2017","journal-title":"Nihon Rinsho Meneki Gakkai Kaishi"},{"key":"B4","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s10875-020-00758-x","article-title":"Human inborn errors of immunity: 2019 update of the iuis phenotypical classification","volume":"40","author":"Bousfiha","year":"2020","journal-title":"J Clin Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nri3897","article-title":"van der Meer JWM, Kullberg BJ, van de Veerdonk LF. Immune defence against Candida fungal infections","volume":"15","author":"Netea","year":"2015","journal-title":"Nat Rev Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1038\/cti.2016.71","article-title":"Chronic mucocutaneous candidiasis disease associated with inborn errors of IL-17 immunity","volume":"5","author":"Okada","year":"2016","journal-title":"Clin Transl Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.coi.2017.10.003","article-title":"Insights into immune tolerance from AIRE deficiency","volume":"49","author":"Proekt","year":"2017","journal-title":"Curr Opin Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/imr.12714","article-title":"Lessons from primary immunodeficiencies: autoimmune regulator and autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy","volume":"287","author":"Constantine","year":"2019","journal-title":"Immunol Rev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1084\/jem.20091669","article-title":"Chronic mucocutaneous candidiasis in APECED or thymoma patients correlates with autoimmunity to Th17-associated cytokines","volume":"207","author":"Kisand","year":"2010","journal-title":"J Exp Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1084\/jem.20091983","article-title":"Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I","volume":"207","author":"Puel","year":"2010","journal-title":"J Exp Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.chom.2016.10.001","article-title":"IL-17 receptor signaling in oral epithelial cells is critical for protection against oropharyngeal candidiasis","volume":"20","author":"Conti","year":"2016","journal-title":"Cell Host Microbe."},{"key":"B12","doi-asserted-by":"publisher","first-page":"780","DOI":"10.4049\/jimmunol.1500909","article-title":"IL-17-mediated immunity to the opportunistic fungal pathogen candida albicans","volume":"195","author":"Conti","year":"2015","journal-title":"J Immunol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1126\/science.1200439","article-title":"Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity","volume":"332","author":"Puel","year":"2011","journal-title":"Science."},{"key":"B14","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/cid\/cir958","article-title":"Photo quiz. A. 32-year-old man with ulcerative mucositis, skin lesions, nail dystrophy. Chronic mucocutaneous candidiasis by multidrug-resistant Candida albicans","volume":"54","author":"Bader","year":"2012","journal-title":"Clin Infect Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"E8277","DOI":"10.1073\/pnas.1618300114","article-title":"Genetic, immunological, and clinical features of patients with bacterial and fungal infections due to inherited IL-17RA deficiency","volume":"113","author":"Levy","year":"2016","journal-title":"Proc Natl Acad Sci USA."},{"key":"B16","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1080\/09546634.2017.1398396","article-title":"Chronic mucocutaneous candidiasis: what can we conclude about IL-17 antagonism?","volume":"29","author":"Veverka","year":"2018","journal-title":"J Dermatolog Treat."},{"key":"B17","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/imm.12938","article-title":"The role of transforming growth factor beta in T helper 17 differentiation","volume":"155","author":"Zhang","year":"2018","journal-title":"Immunology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.coi.2010.06.009","article-title":"Inborn errors of mucocutaneous immunity to Candida albicans in humans: a role for IL-17 cytokines?","volume":"22","author":"Puel","year":"2010","journal-title":"Curr Opin Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3154","DOI":"10.1182\/blood-2015-11-679902","article-title":"Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype","volume":"127","author":"Toubiana","year":"2016","journal-title":"Blood."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1084\/jem.20110958","article-title":"Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis","volume":"208","author":"Liu","year":"2011","journal-title":"J Exp Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.3389\/fimmu.2019.01433","article-title":"STAT1 gain-of-function mutations cause high total STAT1 levels with normal dephosphorylation","volume":"10","author":"Zimmerman","year":"2019","journal-title":"Front Immunol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jaci.2013.09.032","article-title":"Fatal combined immunodeficiency associated with heterozygous mutation in STAT1","volume":"133","author":"Sharfe","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/nature06764","article-title":"Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome","volume":"452","author":"Milner","year":"2008","journal-title":"Nature."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1084\/jem.20080321","article-title":"Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells","volume":"205","author":"de Beaucoudrey Puel","year":"2008","journal-title":"J Exp Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.jaip.2017.06.041","article-title":"Autosomal dominant hyper-IgE syndrome in the USIDNET registry","volume":"6","author":"Gernez","year":"2018","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.iac.2018.08.007","article-title":"An update on syndromes with a hyper-ige phenotype","volume":"39","author":"Bergerson","year":"2019","journal-title":"Immunol Allergy Clin North Am."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.jaci.2009.10.038","article-title":"Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome","volume":"124","author":"Engelhardt","year":"2009","journal-title":"J Allergy Clin Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"eaat4956","DOI":"10.1126\/sciimmunol.aat4956","article-title":"A recessive form of hyper-IgE syndrome by disruption of ZNF341-dependent STAT3 transcription and activity","volume":"3","author":"Beziat","year":"2018","journal-title":"Sci Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.immuni.2006.09.009","article-title":"Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity","volume":"25","author":"Minegishi","year":"2006","journal-title":"Immunity."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1016\/j.jaci.2014.02.025","article-title":"Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels","volume":"133","author":"Sassi","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1016\/j.jaci.2014.02.013","article-title":"Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, neurocognitive impairment","volume":"133","author":"Zhang","year":"2014","journal-title":"J Allergy Clin Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ajhg.2014.05.007","article-title":"PGM3 mutations cause a congenital disorder of glycosylation with severe immunodeficiency and skeletal dysplasia","volume":"95","author":"Stray-Pedersen","year":"2014","journal-title":"Am J Hum Genet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.jaci.2018.08.013","article-title":"Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease","volume":"143","author":"Dorjbal","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"aau6759","DOI":"10.1126\/sciimmunol.aau6759","article-title":"Human IFN-gamma immunity to mycobacteria is governed by both IL-12 and IL-23","volume":"3","author":"Martinez-Barricarte","year":"2018","journal-title":"Sci Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1126\/science.aaa4282","article-title":"IMMUNODEFICIENCIES. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations","volume":"349","author":"Okada","year":"2015","journal-title":"Science."},{"key":"B36","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s10875-019-00664-x","article-title":"Chronic mucocutaneous candidiasis in an adolescent boy due to a novel mutation in TRAF3IP2","volume":"39","author":"Bhattad","year":"2019","journal-title":"J Clin Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.immuni.2013.09.002","article-title":"An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis","volume":"39","author":"Boisson","year":"2013","journal-title":"Immunity."},{"key":"B38","doi-asserted-by":"publisher","first-page":"aax7965","DOI":"10.1126\/sciimmunol.aax7965","article-title":"Chronic mucocutaneous candidiasis and connective tissue disorder in humans with impaired JNK1-dependent responses to IL-17A\/F and TGF-beta","volume":"4","author":"Li","year":"2019","journal-title":"Sci Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1056\/NEJMoa0810719","article-title":"A homozygous CARD9 mutation in a family with susceptibility to fungal infections","volume":"361","author":"Glocker","year":"2009","journal-title":"N Engl J Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"101417","DOI":"10.1016\/j.cimid.2020.101417","article-title":"Complete clinical remission of invasive Candida infection with CARD9 deficiency after G-CSF treatment","volume":"70","author":"Du","year":"2020","journal-title":"Comp Immunol Microbiol Infect Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/bjd.17144","article-title":"Cutaneous mucormycosis caused by mucor irregularis in a patient with CARD9 deficiency","volume":"180","author":"Wang","year":"2019","journal-title":"Br J Dermatol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s10875-019-00740-2","article-title":"Inherited CARD9 deficiency in a patient with both exophiala spinifera and aspergillus nomius severe infections","volume":"40","author":"Perez","year":"2020","journal-title":"J Clin Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1007\/s10875-018-0539-2","article-title":"Inherited CARD9 deficiency: invasive disease caused by ascomycete fungi in previously healthy children and adults","volume":"38","author":"Corvilain","year":"2018","journal-title":"J Clin Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/bjd.17092","article-title":"Recurrent fungal infections in a Chinese patient with CARD9 deficiency and a review of 48 cases","volume":"180","author":"Quan","year":"2019","journal-title":"Br J Dermatol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s10875-019-00662-z","article-title":"Successful allogenic stem cell transplantation in patients with inherited card9 deficiency","volume":"39","author":"Queiroz-Telles","year":"2019","journal-title":"J Clin Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1093\/cid\/ciu215","article-title":"CARD9 deficiency and spontaneous central nervous system candidiasis: complete clinical remission with GM-CSF therapy","volume":"59","author":"Gavino","year":"2014","journal-title":"Clin Infect Dis."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1056\/NEJMoa0901053","article-title":"Human dectin-1 deficiency and mucocutaneous fungal infections","volume":"361","author":"Ferwerda","year":"2009","journal-title":"N Engl J Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1182\/blood-2012-08-450551","article-title":"Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency","volume":"121","author":"Drewniak","year":"2013","journal-title":"Blood."},{"key":"B49","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/cei.13192","article-title":"HDAC inhibitors modulate innate immune responses to micro-organisms relevant to chronic mucocutaneous candidiasis","volume":"194","author":"Rosler","year":"2018","journal-title":"Clin Exp Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s10875-018-0575-y","article-title":"Hematopoietic stem cell transplantation in patients with heterozygous stat1 gain-of-function mutation","volume":"39","author":"Kiykim","year":"2019","journal-title":"J Clin Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jaci.2017.03.049","article-title":"Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription. 1 mutations","volume":"141","author":"Leiding","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1016\/j.jaci.2016.11.022","article-title":"Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation","volume":"139","author":"Weinacht","year":"2017","journal-title":"J Allergy Clin Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1101\/157271","article-title":"Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations","volume":"141","author":"Vargas-Hernandez","year":"2018","journal-title":"J Allergy Clin Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s10875-019-00687-4","article-title":"Novel gain-of-function mutation in stat1 sumoylation site leads to CMC\/CID phenotype responsive to ruxolitinib","volume":"39","author":"Al Shehri","year":"2019","journal-title":"J Clin Immunol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1093\/cid\/ciw020","article-title":"Ruxolitinib induces interleukin 17 and ameliorates chronic mucocutaneous candidiasis caused by STAT1 gain-of-function mutation","volume":"62","author":"Mossner","year":"2016","journal-title":"Clin Infect Dis."},{"key":"B56","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1007\/s12185-020-02860-7","article-title":"Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation","volume":"112","author":"Moriya","year":"2020","journal-title":"Int J Hematol."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.593289\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,16]],"date-time":"2020-10-16T04:36:28Z","timestamp":1602822988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2020.593289\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,16]]},"references-count":56,"alternative-id":["10.3389\/fimmu.2020.593289"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2020.593289","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,16]]},"article-number":"593289"}}